Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Postprandial Somnolence in People with Multiple Sclerosis
Multiple Sclerosis
P10 - Poster Session 10 (5:30 PM-6:30 PM)
9-008

To identify whether people with MS (pwMS) suffer from postprandial somnolence (PPS) more than people without MS (pw/MS), to examine whether the severity of MS is correlated to the severity of PPS and to describe the strategies that pwMS use to manage these symptoms.
It has been observed in clinical practice that pwMS appear to be more sensitive to PPS, but no studies confirming this association have been published.
A cross-sectional study was conducted among pwMS at The Royal London Hospital, London, UK.  Patients completed an online survey including demographics, co-morbidities, a description of their most recent meal and the Stanford Sleepiness Score (SSS). Their siblings, partners and friends were asked to complete a similar survey. Both groups completed the survey one hour after eating lunch. Statistical analysis was performed using SPSS Statistics.
Survey responses of n=77 pwMS (mean age 45.3 +/- 11.5 years; 62.3% female) and n=37 pw/MS (mean age 47.02 +/- 13.9 years; 63.8% female) were gained. The mean SSS for pwMS was 3.46, whilst the mean SSS for pw/MS was 2.52 (p=0.001). No linear correlation was observed between EDSS and SSS (R2=0.011). 63% of pwMS reported making changes to their diet to help their symptoms: these included reducing the portion size, the number of portions eaten in a day and reducing the amount of specific food components consumed (particularly carbohydrates and fat).
PwMS are affected by PPS more than the general population. EDSS was not predictive of PPS severity in pwMS. pwMS are adopting self-management strategies to help reduce their symptoms of PPS. Emerging evidence on MS and PPS should be translated into interventions for health-promoting purposes.
Authors/Disclosures
Tatiana L. Christmas, MD (Northwick Park Hospital)
PRESENTER 		No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
Gavin Giovannoni, MD (QMUL) Dr. Giovannoni has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Giovannoni has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sanofi. Dr. Giovannoni has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Merck KGaA. Dr. Giovannoni has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Roche-Genentech. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Moderna. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sandoz. Dr. Giovannoni has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Astoria Biologica. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Zenas. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Giovannoni has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Medscape.